Publications

Export 55 results:
Auteur Title Type [ Année(Asc)]
Filtres: Mot-clé is Alzheimer Disease  [Enlever les filtres]
2016
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Chung JKu, Plitman E, Nakajima S, M Chakravarty M, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A.  2016.  Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.. J Geriatr Psychiatry Neurol. 29(3):149-59.
Bisht K, Sharma KP, Lecours C, Sánchez MGabriela, Hajj HEl, Milior G, Olmos-Alonso A, Gómez-Nicola D, Luheshi G, Vallières L et al..  2016.  Dark microglia: A new phenotype predominantly associated with pathological states.. Glia. 64(5):826-39.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Leduc V, Théroux L, Dea D, Dufour R, Poirier J.  2016.  Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.. J Mol Neurosci. 58(1):109-19.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Leh SE, Kälin AM, Schroeder C, Park MTae M, M Chakravarty M, Freund P, Gietl AF, Riese F, Kollias S, Hock C et al..  2016.  Volumetric and shape analysis of the thalamus and striatum in amnestic mild cognitive impairment.. J Alzheimers Dis. 49(1):237-49.
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT.  2016.  Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
Fletcher E, Villeneuve S, Maillard P, Harvey D, Reed B, Jagust W, DeCarli C.  2016.  β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.. Neurobiol Aging. 40:173-80.
2015
Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, Brockschnieder D, Dyrks T, Althoff V, Fraser PE et al..  2015.  Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.. J Alzheimers Dis. 44(2):613-24.
Gauthier S, Proaño JVoltaire, Jia J, Froelich L, Vester JChristophe, Doppler E.  2015.  Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dement Geriatr Cogn Disord. 39(5-6):332-47.
Breitner JCS.  2015.  Comment: Yet another "disconnect" between amyloid and Alzheimer disease? Neurology. 85(8):698.
Sankar T, M Chakravarty M, Bescos A, Lara M, Obuchi T, Laxton AW, McAndrews MPat, Tang-Wai DF, Workman CI, Smith GS et al..  2015.  Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease.. Brain Stimul. 8(3):645-54.
Boccardi M, Bocchetta M, Apostolova LG, Barnes J, Bartzokis G, Corbetta G, DeCarli C, deToledo-Morrell L, Firbank M, Ganzola R et al..  2015.  Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance.. Alzheimers Dement. 11(2):126-38.
Rasmussen L, de Labio RW, Viani GA, Chen E, Villares J, Bertolucci P-H, Minett TS, Turecki G, Cecyre D, Drigo SA et al..  2015.  Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer's Disease Patients.. Curr Alzheimer Res. 12(10):984-9.
Frisoni GB, Jack CR, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, Preboske G, Swihart T, Blair M, Cavedo E et al..  2015.  The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity.. Alzheimers Dement. 11(2):111-25.

Pages